Please login to the form below

Not currently logged in
Email:
Password:

Batten disease

This page shows the latest Batten disease news and features for those working in and with pharma, biotech and healthcare.

NICE approves BioMarin’s Brineura after initial setback

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease. BioMarin and NICE had a rocky start with Batten disease therapy Brineura, but the two have now come to an agreement. ... The disease, known as neuronal ceroid lipfuscinosis type 2 (CLN2), is a very rare inherited

Latest news

  • BioMarin ticks over in Q2 ahead of gene therapy filing BioMarin ticks over in Q2 ahead of gene therapy filing

    A second-generation treatment for rare disease phenylketonuria (PKU), the newly launched drug reported $18.8m in sales. ... BioMarin will also hope to extend the commercial success of Brineura, its Batten disease therapy.

  • Amicus forms gene therapy manufacturing partnership with Catalent Amicus forms gene therapy manufacturing partnership with Catalent

    Amicus has one rare disease medicine already on the market, Galafold for Fabry disease, with an enzyme replacement therapy (AT-GAA) for Pompe disease in its late stage pipeline, to which ... capabilities. Thermo Fisher will supply Amicus with immediate

  • NICE knocks back BioMarin’s Batten disease drug NICE knocks back BioMarin’s Batten disease drug

    The committee initially agreed that Brineura shows substantial short-term benefits in slowing down the rate of Batten disease progression in draft guidance, but said BioMarin was unable to price the ... Results from a phase 1 and 2 clinical trial show

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    BioMarin got a green light for Brineura (cerliponase alfa), an enzyme replacement therapy for the ultra-rare neurodegenerative disease neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease that ... There is no approved drug to treat the

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

Actinic keratosis – a common skin condition that can lead to skin cancer
PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...